The Impact of 18F-FDG PET CT Prior to Chemoradiotherapy for Stage III/IV Head and Neck Squamous Cell Carcinoma

Published on Mar 24, 2012in International Scholarly Research Notices
· DOI :10.5402/2012/636379
Robin Prestwich28
Estimated H-index: 28
Priya Bhatnagar2
Estimated H-index: 2
+ 5 AuthorsAndrew Scarsbrook29
Estimated H-index: 29
Introduction. To determine the value of a FDG-PET-CT scan in patients with locally advanced head and neck squamous cell carcinoma (HNSCC) prior to chemoradiotherapy. Materials and Methods. Consecutive patients with stage III or IV HNSCC who had undergone a staging FDG-PET-CT scan prior to chemoradiotherapy between August 2008 and April 2011 were included. Clinical details and conventional imaging (CT and/or MRI) were, retrospectively, reviewed, a TNM stage was assigned, and levels of cervical lymph node involvement were documented. This process was repeated with the addition of FDG-PET-CT. Radiotherapy plans were reviewed for patients with an alteration identified on TNM staging and/or nodal level identification with FDG-PET-CT and potential alterations in radiotherapy planning were documented. Results. 55 patients were included in the analysis. FDG-PET-CT altered the TNM stage in 17/55 (31%) of patients, upstaging disease in 11 (20%) and downstaging in 6 (11%); distant metastases were identified by FDG-PET-CT in 1 (2%) patient. FDG-PET-CT altered the lymph node levels identified in 22 patients (40%), upclassifying disease in 16 (29%) and downclassifying in 6 (11%). Radiotherapy plans were judged retrospectively to have been altered by FDG-PET-CT in 10 patients (18%). Conclusions. The use of FDG-PET-CT potentially impacts upon both treatment decisions and radiotherapy planning.
📖 Papers frequently viewed together
22 Citations
Purpose To report the experience of treating selected fit patients with locally advanced head-and-neck squamous cell carcinoma with three cycles of induction TPF (docetaxel 75 mg/m 2 , cisplatin 75 mg/m 2 , 5-fluorouracil 750 mg/m 2 , Days 2–5) followed by concurrent three-weekly bolus cisplatin 100 mg/m 2 chemoradiotherapy. Methods and Materials Between March 2006 and February 2010, 66 patients with nonmetastatic Stage IV head-and-neck squamous cell carcinoma were treated in a single institutio...
31 CitationsSource
#1Christopher M. Nutting (ICR: Institute of Cancer Research)H-Index: 69
#2James P Morden (ICR: Institute of Cancer Research)H-Index: 21
Last. Emma Hall (ICR: Institute of Cancer Research)H-Index: 57
view all 18 authors...
Summary Background Xerostomia is the most common late side-effect of radiotherapy to the head and neck. Compared with conventional radiotherapy, intensity-modulated radiotherapy (IMRT) can reduce irradiation of the parotid glands. We assessed the hypothesis that parotid-sparing IMRT reduces the incidence of severe xerostomia. Methods We undertook a randomised controlled trial between Jan 21, 2003, and Dec 7, 2007, that compared conventional radiotherapy (control) with parotid-sparing IMRT. We ra...
1,025 CitationsSource
#1Robin Prestwich (St James's University Hospital)H-Index: 28
#2Kiran Kancherla (St James's University Hospital)H-Index: 3
Last. Mehmet Sen (St James's University Hospital)H-Index: 18
view all 7 authors...
Background Chemo-radiotherapy offers an alternative to primary surgery and adjuvant therapy for the management of locally advanced stage IV squamous cell carcinomas of the tonsil.
25 CitationsSource
#1Esther G.C. Troost (Radboud University Nijmegen Medical Centre)H-Index: 36
#2Dominic A.X. Schinagl (Radboud University Nijmegen Medical Centre)H-Index: 12
Last. Johannes H.A.M. Kaanders (Radboud University Nijmegen Medical Centre)H-Index: 49
view all 5 authors...
Abstract The potential benefits of positron emission tomography (PET) imaging for the management of head and neck tumours are increasingly being recognized. Integrated PET–CT has found its way into the practice of radiation oncology providing both functional and anatomical tumour information for treatment planning and the implications for clinical practice are currently being investigated. First, it has been demonstrated that 18 F-fluorodeoxyglucose ( 18 FDG)-PET can improve the accuracy of gros...
113 CitationsSource
#1John Aldo Lee (UCL: Université catholique de Louvain)H-Index: 48
Positron emission tomography can be used in radiation oncology for the delineation of target volumes in the treatment planning stage. Numerous publications deal with this topic and the scientific community has investigated many methodologies, ranging from simple uptake thresholding to very elaborate probabilistic models. Nevertheless, no consensus seems to emerge. This paper reviews delineation techniques that are popular in the literature. Special attention is paid to threshold-based techniques...
160 CitationsSource
#1Gregory J. Kubicek (KU: University of Kansas)H-Index: 15
#2Collin Champ (Thomas Jefferson University Hospital)H-Index: 1
Last. Mitchell Machtay (Case Western Reserve University)H-Index: 31
view all 8 authors...
Objectives The role of positron emission tomography (PET) with fluoro-deoxy-glucose (FDG) in the staging of head and neck cancer (HNC) is unclear. The NCCN guidelines do not recommend FDG-PET as a part of standard workup. The purpose of this report is to examine the role of FDG-PET imaging in altering management and providing prognostic information for HNC.
104 CitationsSource
#1Johan Bussink (Radboud University Nijmegen Medical Centre)H-Index: 33
#2Carla M.L. van Herpen (Radboud University Nijmegen Medical Centre)H-Index: 19
Last. Wim J.G. Oyen (Radboud University Nijmegen Medical Centre)H-Index: 110
view all 4 authors...
Summary Preferred treatment strategies for advanced-stage squamous cell carcinoma of the head and neck have shifted from surgery to organ-preservation approaches such as radiotherapy, which can be combined with chemotherapy or giving of biologically modifying molecules. Preclinical and clinical researchers aim to customise these treatments on the basis of biological tumour characteristics, including tumour cell proliferation, hypoxia, and apoptosis—important resistance mechanisms for cytotoxic a...
111 CitationsSource
#1Lester J. Peters (Peter MacCallum Cancer Centre)H-Index: 57
#1Lester J. Peters (Peter MacCallum Cancer Centre)H-Index: 74
Last. Danny RischinH-Index: 69
view all 10 authors...
Purpose To report the impact of radiotherapy quality on outcome in a large international phase III trial evaluating radiotherapy with concurrent cisplatin plus tirapazamine for advanced head and neck cancer. Patients and Methods The protocol required interventional review of radiotherapy plans by the Quality Assurance Review Center (QARC). All plans and radiotherapy documentation underwent post-treatment review by the Trial Management Committee (TMC) for protocol compliance. Secondary review of ...
562 CitationsSource
#1Max Lonneux (Cliniques Universitaires Saint-Luc)H-Index: 27
#2Marc HamoirH-Index: 41
Last. Vincent GrégoireH-Index: 70
view all 10 authors...
Purpose To address the impact of positron emission tomography with [18F]fluorodeoxyglucose (PET-FDG) on the initial staging and management of patients with head and neck squamous cell carcinoma (HNSCC). Patients and Methods This multicenter, prospective study included 233 patients with newly diagnosed and untreated HNSCC. TNM stage and therapeutic decision were first determined based on the conventional work-up (including physical examination, computed tomography [CT]/magnetic resonance imaging ...
251 CitationsSource
#1June Corry (University of Melbourne)H-Index: 47
#2Lester J. Peters (University of Melbourne)H-Index: 57
Last. Danny Rischin (University of Melbourne)H-Index: 69
view all 3 authors...
Summary The intensity of contemporary treatment for locally advanced head and neck cancer is at the upper limit of human tolerance of acute toxicities. While impressive gains in locoregional control have been achieved, improvements in overall survival have been more modest. We hypothesise that unrecognised sequelae of highly toxic contemporary treatments substantially contribute to patient mortality. This possibility provides motivation to investigate reducing treatment intensity in selected pat...
80 CitationsSource
Cited By5
#1Max Rohde (University of Southern Denmark)H-Index: 6
#2Anne Lerberg Nielsen (OUH: Odense University Hospital)H-Index: 15
Last. Christian Godballe (University of Southern Denmark)H-Index: 30
view all 13 authors...
Purpose In patients with newly diagnosed head and neck squamous cell carcinoma (HNSCC), we wanted to examine the differences in overall treatment decisions, i.e. curative versus palliative treatment intent, reached by a multidisciplinary team conference (MDTC) based on 18F–fluoro-deoxy-glucose-positron emission tomography/computed tomography (PET/CT) or chest X-ray + MRI of the head and neck (CXR/MRI).
10 CitationsSource
#1A.M. García Vicente (RAFAEL: Rafael Advanced Defense Systems)H-Index: 10
#2A. Soriano Castrejón (RAFAEL: Rafael Advanced Defense Systems)H-Index: 10
Last. G. Andrés Jiménez Londoño (RAFAEL: Rafael Advanced Defense Systems)H-Index: 1
view all 3 authors...
Abstract 18 F-FDG-PET-CT has showed its utility in the staging and the definition of the treatment volume in head and neck cancers with radiotherapy (RT) indication. Despite some uncertainties related to resolution and segmentation, PET/CT offers valuable information about tumor heterogeneity and biology. The technological advances in the radiotherapy setting as intensity-modulated RT, image-guided RT in the adaptive protocol and dose escalation are the future directions for the PET-CT especiall...
1 CitationsSource
#1Vincent GrégoireH-Index: 70
#1Vincent GrégoireH-Index: 9
Last. Joan VlayenH-Index: 2
view all 18 authors...
Positron emission tomography (PET) with [18F]fluoro-2-deoxy-D-glucose (FDG) has proven to be a valuable diagnostic modality in various diseases. Its accuracy has been improved with the hybrid PET/computed tomography (CT) technique because of precise anatomic location of areas of abnormal FDG accumulation. This integrated PET/CT modality has been widely adopted, particularly in oncology. This paper reviews the role of FDG-PET/CT imaging in breast cancer, non-small-cell lung cancer, colorectal can...
21 CitationsSource
#1Giovana R. Thomas (UM: University of Miami)H-Index: 10
#1Lisa LicitraH-Index: 67
Last. John M. Holland (OHSU: Oregon Health & Science University)H-Index: 19
view all 3 authors...
Head and neck cancer (HNC) is a devastating disease that affects some of the most basic daily functions such as breathing, speaking, and swallowing. Because of its visible nature, HNC is also associated with significant disfigurement. The combined effect of disability and disfigurement and the added toxicity of treatment greatly increase symptom burden and reduce physical, emotional, and social functioning. Since its inception, the Head and Neck Oncology Program at MD Anderson Cancer Center has ...
10 CitationsSource